Kolexia
Escoffre-Barbe Martine
Hématologie
Hôpital Pontchaillou
Rennes, France
186 Activités
0 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Myélome multiple Leucémie myéloïde chronique BCR-ABL positive Leucémie-lymphome lymphoblastique à précurseurs B et T Leucémie myéloïde Tumeurs à plasmocytes Chromosome Philadelphie Maladie résiduelle Leucémie lymphoïde

Industries

Novartis
5 collaboration(s)
Dernière en 2023
Janssen
4 collaboration(s)
Dernière en 2023
B3TSI
3 collaboration(s)
Dernière en 2020
Amgen
2 collaboration(s)
Dernière en 2023

Dernières activités

Nilotinib with or without cytarabine for Philadelphia positive acute lymphoblastic leukemia.
Blood   07 mars 2024
BIO-TIMER: Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated With Targeted Therapy: the Model of Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors.
Essai Clinique (CHU Clermont-Ferrand)   29 février 2024
Daratumumab Carfilzomib Lenalidomide and Dexamethasone with tandem transplant in high-risk newly diagnosed myeloma.
Blood   23 février 2024
Low non-relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Société Francophone de Greffe de Moelle-Thérapie Cellulaire observational study.
British journal of haematology   12 novembre 2023
Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence
65th ASH Annual Meeting Abstracts   02 novembre 2023
Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report
65th ASH Annual Meeting Abstracts   02 novembre 2023
Frontline Consolidation with Nelarabine for Adults with High-Risk T-Cell Acute Lymphoblastic Leukemia. Results of the Graall-2014/T Atriall Phase 2 Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Exploring the Heterogeneity of Response to Blinatumomab in High-Risk Philadelphia-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: An Analysis from the QUEST Sub-Study of the Graall-2014/B Trial
65th ASH Annual Meeting Abstracts   02 novembre 2023
Genetic alterations and MRD refine risk assessment within KMT2A-rearranged B-cell precursor ALL in adult: a GRAALL study.
Blood   18 août 2023